<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> in <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> has become one of the focal points of research studies </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001844'>Autoimmune response</z:mp> and autoreactive autoantibodies have been found in <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo>, rheumatic <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:mp ids='MP_0001856'>myocarditis</z:mp>, <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, and other diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Autoantibodies may appear due to tissue injury and exposure of autoantigens, in addition to molecular mimicry and cross-reactivity with antigens found in infectious agents in predisposed individuals </plain></SENT>
<SENT sid="3" pm="."><plain>In the early 1990s, autoantibodies reacting with the M2 muscarinic receptor were found in patients with <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> and subsequently, in patients with Chagas <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and arrhythmic disorders </plain></SENT>
<SENT sid="4" pm="."><plain>Immunization of animals with the corresponding antigen triggered <z:hpo ids='HP_0001627'>cardiac abnormalities</z:hpo> also appearing in <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> of humans </plain></SENT>
<SENT sid="5" pm="."><plain>It has been suggested that antibodies against M2 muscarinic receptors play a role in the pathogenesis of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> and may also alter the electrophysiological properties of cardiac tissue </plain></SENT>
<SENT sid="6" pm="."><plain>Herein, we review the current knowledge of antibodies against M2 muscarinic receptors and the possible use of a targeted therapy against these autoantibodies </plain></SENT>
</text></document>